ARS Pharmaceuticals, Inc.
SPRYHeld by 9 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying9 funds opened new positions. Next phase2 readout (Placebo): Jun 2026. Short interest: 38.1% of float.
Held by 9 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying9 funds opened new positions. Next phase2 readout (Placebo): Jun 2026. Short interest: 38.1% of float.
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.